現在の所属組織 【 表示 ／ 非表示 】

現在の所属組織 【 表示 ／ 非表示 】

出身大学 【 表示 ／ 非表示 】

出身大学 【 表示 ／ 非表示 】

出身大学院 【 表示 ／ 非表示 】

出身大学院 【 表示 ／ 非表示 】

留学歴 【 表示 ／ 非表示 】

留学歴 【 表示 ／ 非表示 】

取得学位 【 表示 ／ 非表示 】

取得学位 【 表示 ／ 非表示 】

所属学会・委員会 【 表示 ／ 非表示 】

所属学会・委員会 【 表示 ／ 非表示 】

研究キーワード 【 表示 ／ 非表示 】

研究キーワード 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study

  Mineaki Kitamura, Takahiro Takazono, Kazuko Yamamoto, Takashi Harada, Satoshi Funakoshi, Hiroshi Mukae, Tomoya Nishino

  Renal Replacement Therapy ( Springer Science and Business Media LLC )  8 ( 1 ) 8 - 8   2022年12月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  Abstract Background Patients on hemodialysis (HD) face a high mortality risk from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and they are therefore prioritized for vaccination. However, the efficacy of vaccination in this vulnerable population has not been confirmed. Although age is negatively correlated with serum immunoglobulin (Ig) levels, humoral responses to vaccination in elderly patients undergoing HD have not been investigated. To address this issue, we evaluated the anti-SARS-CoV-2 spike protein antibodies in nursing home residents on HD after BNT162b2 vaccine administration. Methods Patients on HD from a nursing home and care workers (controls) receiving two doses of the BNT162b2 vaccine between April and May 2021 were enrolled in this study. Those with a prior history of COVID-19 were excluded. Anti-spike protein antibodies were measured with the Elecsys (Roche) immunoassay system. Results The study included 26 nursing home residents (41% male; median age, 86 years) and 184 care workers (28% male; median age, 45 years). The median HD vintage was 51 months. After two doses of BNT162b2, 73% of the nursing home residents and 99.5% of the control group developed sufficient anti-spike protein antibodies (> 29 U/mL) to neutralize SARS-CoV-2. Three weeks after the second dose, median IgG titers of the residents and care workers were 83 [interquartile range (IQR) 17–511] and 1365 (IQR 847–2245) U/mL, respectively (p < 0.001). Conclusions The humoral response to BNT162b2 among elderly HD patients was relatively low; therefore, the optimal vaccination strategy for this population should be studied further to avoid COVID-19 outbreaks in healthcare facilities.

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

• Evaluation of a Triage Checklist for Mild COVID-19 Outpatients in Predicting Subsequent Emergency Department Visits and Hospitalization during the Isolation Period: A Single-Center Retrospective Study

  Yasuhiro Tanaka, Kazuko Yamamoto, Shimpei Morimoto, Takeshi Nabeshima, Kayoko Matsushima, Hiroshi Ishimoto, Nobuyuki Ashizawa, Tatsuro Hirayama, Kazuaki Takeda, Hiroshi Gyotoku, Naoki Iwanaga, Shinnosuke Takemoto, Susumu Fukahori, Takahiro Takazono, Hiroyuki Yamaguchi, Takashi Kido, Noriho Sakamoto, Naoki Hosogaya, Shogo Akabame, Takashi Sugimoto, Hirotomo Yamanashi, Kosuke Matsui, Mai Izumida, Ayumi Fujita, Masato Tashiro, Takeshi Tanaka, Koya Ariyoshi, Akitsugu Furumoto, Kouichi Morita, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae

  Journal of Clinical Medicine ( MDPI AG )  11 ( 18 ) 5444 - 5444   2022年09月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  Managing mild illness in COVID-19 and predicting progression to severe disease are concerning issues. Here, we investigated the outcomes of Japanese patients with mild COVID-19, and identified triage risk factors for further hospitalization and emergency department (ED) visits at a single tertiary hospital. A triage checklist with 30 factors was used. Patients recommended for isolation were followed up for 10 days for subsequent ED visits or hospital admission. Overall, 338 patients (median age, 44.0; 45% women) visited the clinic 5.0 days (median) after symptom onset. Thirty-six patients were immediately hospitalized following triage; others were isolated. In total, 72 non-hospitalized patients visited the ED during their isolation, and 30 were hospitalized after evaluation for oxygen desaturation. The median ED visit and hospitalization durations after symptom onset were 5.0 and 8.0 days, respectively. The checklist factors associated with hospitalization during isolation were age > 50 years, body mass index > 25 kg/m2, hypertension, tachycardia with pulse rate > 100/min or blood pressure > 135 mmHg at triage, and >3-day delay in hospital visit after symptom onset. No patients died. Altogether, 80% of patients with mild COVID-19 could be safely isolated at home. Age, BMI, underlying hypertension, date after symptom onset, tachycardia, and systolic blood pressure at triage might be related to later hospitalization.

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

• Efficacy of <i>Lactococcus lactis</i> strain plasma (LC-Plasma) in easing symptoms in patients with mild COVID-19: protocol for an exploratory, multicentre, double-blinded, randomised controlled trial (PLATEAU study)

  Kazuko Yamamoto, Naoki Hosogaya, Tsuyoshi Inoue, Kenta Jounai, Ryohei Tsuji, Daisuke Fujiwara, Katsunori Yanagihara, Koichi Izumikawa, Hiroshi Mukae

  BMJ Open ( BMJ )  12 ( 9 ) e061172 - e061172   2022年09月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  Introduction The COVID-19 pandemic has been a major concern worldwide; however, easily accessible treatment options for patients with mild COVID-19 remain limited. Since the oral intake of Lactococcus lactis strain plasma (LC-Plasma) enhances both the innate and acquired immune systems through the activation of plasmacytoid dendritic cells (pDCs), we hypothesised that the oral intake of LC-Plasma could aid the relief or prevention of symptoms in patients with asymptomatic or mild COVID-19. Methods and analysis This is an exploratory, multicentre, double-blinded, randomised, placebo-controlled trial. This study was initiated in December 2021 and concludes in April 2023. The planned number of enrolled subjects is 100 (50 subjects×2 groups); subject enrolment will be conducted until October 2022. Patients with asymptomatic or mild COVID-19 will be enrolled and randomly assigned in a 1:1 ratio to group A (oral intake of LC-Plasma-containing capsule, 200 mg/day, for 14 days) or group B (oral intake of placebo capsule, for 14 days). The primary endpoint is the change in subjective symptoms measured by the severity score. Secondary endpoints include SARS-CoV-2 viral loads, biomarkers for pDC activation, serum SARS-CoV-2-specific antibodies, serum cytokines, interferon and interferon-inducible antiviral effectors and the proportion of subjects with emergency room visits to medical institutions or who are hospitalised. Ethics and dissemination The study protocol was approved by the Clinical Research Review Board of Nagasaki University, in accordance with the Clinical Trials Act of Japan. The study will be conducted in accordance with the Declaration of Helsinki, the Clinical Trials Act, and other current legal regulations in Japan. Written informed consent will be obtained from all the participants. The results of this study will be reported in journal publications. Trial registration number Japan Registry of Clinical Trials (registration number: jRCTs071210097).

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

• Clinical Differentiation of Severe Fever with Thrombocytopenia Syndrome from Japanese Spotted Fever

  Nana Nakada, Kazuko Yamamoto, Moe Tanaka, Hiroki Ashizawa, Masataka Yoshida, Asuka Umemura, Yuichi Fukuda, Shungo Katoh, Makoto Sumiyoshi, Satoshi Mihara, Tsutomu Kobayashi, Yuya Ito, Nobuyuki Ashizawa, Kazuaki Takeda, Shotaro Ide, Naoki Iwanaga, Takahiro Takazono, Masato Tashiro, Takeshi Tanaka, Seiko Nakamichi, Konosuke Morimoto, Koya Ariyoshi, Kouichi Morita, Shintaro Kurihara, Katsunori Yanagihara, Akitsugu Furumoto, Koichi Izumikawa, Hiroshi Mukae

  Viruses ( MDPI AG )  14 ( 8 ) 1807 - 1807   2022年08月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  Severe fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever (JSF; a spotted fever group rickettsiosis) are tick-borne zoonoses that are becoming a significant public health threat in Japan and East Asia. Strategies for treatment and infection control differ between the two; therefore, initial differential diagnosis is important. We aimed to compare the clinical characteristics of SFTS and JSF based on symptomology, physical examination, laboratory data, and radiography findings at admission. This retrospective study included patients with SFTS and JSF treated at five hospitals in Nagasaki Prefecture, western Japan, between 2013 and 2020. Data from 23 patients with SFTS and 38 patients with JSF were examined for differentiating factors and were divided by 7:3 into a training cohort and a validation cohort. Decision tree analysis revealed leukopenia (white blood cell [WBC] &lt; 4000/μL) and altered mental status as the best differentiating factors (AUC 1.000) with 100% sensitivity and 100% specificity. Using only physical examination factors, absence of skin rash and altered mental status resulted in the best differentiating factors with AUC 0.871, 71.4% sensitivity, and 90.0% specificity. When treating patients with suspected tick-borne infection, WBC &lt; 4000/µL, absence of skin rash, and altered mental status are very useful to differentiate SFTS from JSF.

  • この論文にアクセスする
    DOI

• A Case of Pulmonary Langerhans Cell Histiocytosis That Progressed From a Single-system to a Multisystem Form Despite Smoking Cessation: A Case Report.

  Hiroshi Ishimoto, Noriho Sakamoto, Mutsumi Ozasa, Takeharu Katoh, Hidehiro Itonaga, Makoto Wataya, Daisuke Takao, Atsuko Hara, Takashi Kido, Hiroyuki Yamaguchi, Kazuko Yamamoto, Yasushi Obase, Yuji Ishimatsu, Yasushi Miyazaki, Hiroshi Mukae

  Internal medicine (Tokyo, Japan)   62 ( 6 ) 877 - 880   2022年08月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  A 36-year-old Japanese man presented with cavities and nodular shadows in the lower lobes of his lungs and osteolytic lesions in the thoracic spine. He was diagnosed with multisystem Langerhans cell histiocytosis (LCH). Three years earlier, he had been noted to have small cavities and granular lesions noted in the upper lobes of his lungs, which later improved with smoking cessation. It was likely that his single-system pulmonary LCH (PLCH) progressed to multisystem LCH despite smoking cessation. Relapse or progression may occur in cases where PLCH lesions improve after smoking cessation. Thus, close follow-up is vital.

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

全件表示 >>

著書 【 表示 ／ 非表示 】

著書 【 表示 ／ 非表示 】

• おなかぺこぺこたべちゃおうかな?

  山本 和子 , 鈴木 えりん ( 担当: 単著 )

  学研教育みらい  2022年

• Race, rights, and national security : law and the Japanese American incarceration

  Yamamoto Eric K., Bannai Lorraine J., Chon Margaret ( 担当: 単著 )

  Wolters Kluwer  2021年

• たっちたっち

  あべ つせこ, 山本 和子 ( 担当: 単著 )

  世界文化社  2019年

• だっこだっこ

  あべ つせこ, 山本 和子 ( 担当: 単著 )

  世界文化社  2019年

• Pulmonary Disease Series: Clinical relevance of genetic factors in pulmonary diseases.

  山本和子, 迎 寛 ( 担当: 分担執筆 , 担当範囲: Mycobacterial infection: TB and NTM- what are the roles of genetic factors in the pathogenesis of mycobacterial infection? )

  Springer  2018年06月

全件表示 >>

MISC（その他業績・査読無し論文等） 【 表示 ／ 非表示 】

MISC（その他業績・査読無し論文等） 【 表示 ／ 非表示 】

• HapE変異を有した患者由来アゾール耐性A.fumigatusの表現型評価

  伊藤 裕也, 高園 貴弘, 田代 将人, 西條 知見, 山本 和子, 今村 圭文, 宮崎 泰可, 柳原 克紀, 泉川 公一, 迎 寛

  日本医真菌学会雑誌 ( (一社)日本医真菌学会 )  60 ( Suppl.1 ) 87 - 87   2019年10月

   

• Aspergillus fumigatus臨床分離株の抗真菌薬感受性の経年推移とその臨床的解釈

  高園 貴弘, 伊藤 裕也, 田代 将人, 西條 知見, 山本 和子, 今村 圭文, 宮崎 泰可, 泉川 公一, 柳原 克紀, 迎 寛

  日本化学療法学会雑誌 ( (公社)日本化学療法学会 )  67 ( 2 ) 244 - 245   2019年03月

   

• アンケート調査結果から見える終末期肺炎診療に対する本人,家族,主治医の認識の違い

  高園 貴弘, 今村 圭文, 西條 知見, 山本 和子, 宮崎 泰可, 迎 寛

  日本呼吸器学会誌 ( (一社)日本呼吸器学会 )  8 ( 増刊 ) 234 - 234   2019年03月

   

• アスペルギルス気道感染に伴う血清中サイトカインの検討

  伊藤 裕也, 高園 貴弘, 田代 将人, 西條 知見, 山本 和子, 今村 圭文, 宮崎 泰可, 河野 哲也, 福島 千鶴, 尾長谷 靖, 柳原 克紀, 泉川 公一, 迎 寛

  日本呼吸器学会誌 ( (一社)日本呼吸器学会 )  8 ( 増刊 ) 174 - 174   2019年03月

   

• DPCデータベースを用いた非HIV感染例におけるクリプトコックス髄膜炎の予後因子に関する検討

  日高 悠介, 高園 貴弘, 田代 将人, 伏見 清秀, 西條 知見, 山本 和子, 今村 圭文, 宮崎 泰可, 柳原 克紀, 迎 寛, 泉川 公一

  感染症学雑誌 ( (一社)日本感染症学会 )  93 ( 臨増 ) 361 - 361   2019年03月

   

全件表示 >>

研究発表等の成果普及活動 【 表示 ／ 非表示 】

研究発表等の成果普及活動 【 表示 ／ 非表示 】

• Immunological response to anti-SARS-CoV-2 mRNA vaccines in patients with rheumatoid arthritis

  Kazuko Yamamoto, Tomohiro Koga, Kunihiro Ichinose, Remi Sumiyoshi, Shota Kurushima, Toshimasa Shimizu, Toru Michitsuji, Yoshika Tsuji, Shinya Nishihata, Naoki Iwamoto, Masataka Umeda, Tomoki Origuchi, Mami Tamai, Akimoto Okada, Masako Furuyama, Kunihiko Umekita, Yuya Fujita, Kiyoshi Migita, Atsushi Kawakami, Hiroshi Mukae

  第66回日本リウマチ学会・学術集会  2022年04月  -  2022年04月   

• COVIREGI-JP第１〜4波データを用いたCOVID-19呼吸不全患者における非侵襲性呼吸管理法の実態調査と有用性の検討

  山本和子, 富井啓介, 泉 信有, 石本裕士, 高園貴弘, 岩永直樹, 芦澤信之, 竹本 真之輔, 尾長谷 靖, 田代将人, 田中健之, 山内桃子, 細萱直希, 泉川公一, 柳原克紀, 迎 寛

  第62回日本呼吸器学会学術講演会  2022年04月  -  2022年04月   

• COVIREGI-JP第１〜4波データを用いたCOVID-19呼吸不全患者における細菌合併感染の実態調査と予後の検討

  山本和子, 田中康大, 武田和明, 岩永直樹, 芦澤信之, 高園貴弘, 城戸貴志, 石本裕士, 坂本憲穂, 尾長谷 靖, 田代将人, 藤田あゆみ, 田中健之, 赤羽目翔悟, 松井昂介, 泉田真生, 山梨啓友, 有吉紅也, 古本朗嗣, 泉川公一, 柳原克紀, 迎 寛

  第96回 日本感染症学会総会・学術集会  2022年04月  -  2022年04月   

• Relationship between the Opacity Variance of Streptococcus pneumoniae Colonies and the Clinical Features of Adult Pneumococcal Pneumonia

  Kazuko Yamamoto

  The 3rd Asian Pneumococcal Symposium  2021年12月  -  2021年12月   

• COVID-19の現状

  山本和子

  第9回日本白内障屈折矯正手術学会 ウインターセミナー  2020年12月  -  2021年01月   

全件表示 >>

科研費獲得情報 【 表示 ／ 非表示 】

科研費獲得情報 【 表示 ／ 非表示 】

• ELISPOTを用いたCOVID-19患者の末梢血単核球インターフェロンγ遊離解析とSARS-CoV2ウイルスのもつ抗酸菌特異抗原類似蛋白の同定

  ■■■

  課題番号: 00000000

  研究期間: 2021年09月  -  2022年03月 

• COVID-19呼吸不全患者の予後および合併症回避におけるhigh flow nasal cannula療法の有効性の検討

  ■■■

  課題番号: 00000000

  研究期間: 2021年08月  -  2022年03月 

  直接経費: 5,593,000（円）  間接経費: 7,990,000（円）  金額合計: 2,397,000（円）

• hsdS遺伝子組換え膜光透過性固定株を用いた侵襲性肺炎球菌感染症のメカニズム解明

  基盤研究(C)

  課題番号: 21K08506

  研究期間: 2021年04月  -  2024年03月 

  代表者: 山本 和子 

  直接経費: 3,300,000（円）  間接経費: 4,290,000（円）  金額合計: 990,000（円）

• Roles of T follicular helper cells and tissue resident memory cells of mucosal immunity in COVID-19 disease severity

  戦略的国際共同研究プログラム（SICORP）日米医学協力計画の若手・女性育成のための日米共同研究公募

  課題番号: 00000000

  研究期間: 2021年01月  -  2022年03月 

  直接経費: 7,500,000（円）  間接経費: 10,000,000（円）  金額合計: 3,000,000（円）

学外の社会活動（高大・地域連携等） 【 表示 ／ 非表示 】

学外の社会活動（高大・地域連携等） 【 表示 ／ 非表示 】

• インフルエンザと肺炎. その密接な関係と予防法.

  日本呼吸器学会  市民公開講座 

  2018年10月

  　

  　

• Study Abroad!

  Japan Global Medical Career Support  第6回JGMS講演会 

  2015年02月